Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma: a Multicenter, Observational, Real-world Study

NCT06323382 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06323382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06323382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma: a Multicenter, Observational, Real-world Study
Lead sponsor
Sun Yat-sen University
Phase
Observational
Overall status
Recruiting
Start date
January 1, 2021
Completion date
December 30, 2025
Enrollment
240 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma, anti-pd1/pdl1 antibody, bevacizumab